Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemiaNicolas Boissel, Delphine Rea, Vannary Tieng, et al.
Blood|April 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminibAriel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, et al.
Oncotarget|May 12, 2016
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationJean Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq)Guillaume Gricourt, Violaine Tran Quang, Jean-Michel Cayuela, et al.
Haematologica|July 10, 2025
Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN surveyFabian Lang, Zack Pemberton-Whiteley, Joannie Clements, et al.
Leukemia|January 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath resultsDelphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Leukemia|July 31, 2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibAriel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, et al.
Leukemia & Lymphoma|October 25, 2019
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyNeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemiaNicolas Boissel, Delphine Rea, Vannary Tieng, et al.
Blood|April 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminibAriel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, et al.
Oncotarget|May 12, 2016
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationJean Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq)Guillaume Gricourt, Violaine Tran Quang, Jean-Michel Cayuela, et al.
Haematologica|July 10, 2025
Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN surveyFabian Lang, Zack Pemberton-Whiteley, Joannie Clements, et al.
Leukemia|January 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath resultsDelphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Leukemia|July 31, 2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibAriel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, et al.
Leukemia & Lymphoma|October 25, 2019
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyNeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Pageof 11